KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) EBT (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed EBT for 16 consecutive years, with -$17.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 12.76% to -$17.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$84.4 million through Dec 2025, up 21.71% year-over-year, with the annual reading at -$84.4 million for FY2025, 21.71% up from the prior year.
  • EBT hit -$17.0 million in Q4 2025 for Inovio Pharmaceuticals, up from -$20.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$17.0 million in Q4 2025 to a low of -$108.5 million in Q2 2022.
  • Historically, EBT has averaged -$45.4 million across 5 years, with a median of -$34.7 million in 2023.
  • Biggest five-year swings in EBT: plummeted 387.46% in 2021 and later surged 67.25% in 2023.
  • Year by year, EBT stood at -$106.9 million in 2021, then skyrocketed by 49.07% to -$54.5 million in 2022, then skyrocketed by 54.09% to -$25.0 million in 2023, then increased by 21.94% to -$19.5 million in 2024, then increased by 12.76% to -$17.0 million in 2025.
  • Business Quant data shows EBT for INO at -$17.0 million in Q4 2025, -$20.7 million in Q3 2025, and -$22.5 million in Q2 2025.